S&P 500
7,806.00
-0.04%
Dow Jones
53,899.70
+0.02%
Nasdaq 100
30,060.00
-0.24%
Russell 2000
3,052.23
-0.07%
FTSE 100
10,796.30
-0.02%
Nikkei 225
68,665.50
-0.66%
Nektar Therapeutics

Nektar Therapeutics (NKTR) Q2 2026 Earnings

Reported Aug 13, 2026 at 4:25 PM ET · SEC Source

Q2 26 EPS GAAP

$-1.23

BEAT +39.63%

Est. $-2.04

Q2 26 Revenue

$10.1M

MISS 3.24%

Est. $10.5M

Market Reaction

Did NKTR Beat Earnings? Q2 2026 Results

Nektar Therapeutics delivered a sharper-than-expected loss for Q2 2026, with GAAP EPS of $-1.23 per diluted share beating the consensus estimate of $-2.04 by 39.63%, even as revenue of $10.13 million slipped 3.24% below expectations and fell 9.3% yea… Read more Nektar Therapeutics delivered a sharper-than-expected loss for Q2 2026, with GAAP EPS of $-1.23 per diluted share beating the consensus estimate of $-2.04 by 39.63%, even as revenue of $10.13 million slipped 3.24% below expectations and fell 9.3% year over year. The key driver behind the narrower per-share loss was a more than doubling of weighted average shares outstanding following the company's April 2026 public offering, which raised $373.80 million in gross proceeds and pushed the cash and investments balance to approximately $1.02 billion by quarter-end. That war chest, management noted, extends the company's runway into Q3 2028, conveniently past the mid-2028 data readouts expected from the Phase 3 ZENITH AD program in atopic dermatitis, which launched in July with three registrational trials. R&D expense climbed to $39.13 million from $29.89 million a year ago as the program ramped, while revenue, consisting entirely of non-cash royalties, remained a nominal contributor. With a BLA submission targeted for 2029 and a Phase 3 alopecia areata study planned for early 2027, investor attention is squarely on clinical execution rather than near-term financials.

Key Takeaways

  • • R&D expense increase driven by Phase 3 ZENITH AD program commencement and rezpegaldesleukin manufacturing activities
  • • G&A expense decrease primarily due to lower legal expenses
  • • Interest income surged due to significantly larger cash and investment position following April 2026 equity offering
  • • Non-cash loss from equity method investment in Gannet BioChem narrowed significantly

NKTR Forward Guidance & Outlook

Nektar plans to initiate a single registrational Phase 3 study of rezpegaldesleukin in alopecia areata in early 2027. The Phase 3 ZENITH AD program in atopic dermatitis was initiated in July 2026 with three randomized, double-blind, placebo-controlled trials. The company targets a first BLA submission for rezpegaldesleukin in 2029, with initial Phase 3 data readouts expected in mid-2028. Management stated that the company's cash runway extends into Q3 2028, past initial Phase 3 data readouts.

24/7 Wall St

NKTR YoY Financials

Q2 2026 vs Q2 2025, source: SEC Filings

24/7 Wall St

NKTR Revenue by Segment

With YoY comparisons, source: SEC Filings

Q2 25 Q4 25

“This year continues to be a transformative year for Nektar as we advance our lead program, rezpegaldesleukin, into Phase 3 clinical trials. We initiated the first Phase 3 ZENITH AD trials in atopic dermatitis in July, and we plan to start a single registrational Phase 3 study in alopecia areata in early 2027. Our Phase 3 program establishes a clear path to the first BLA submission for rezpegaldesleukin in 2029. With its novel T-reg mechanism, rezpegaldesleukin is uniquely positioned to provide benefit for patients across a number of chronic autoimmune conditions. Importantly, our financial position is strong with over one billion dollars in cash and investments at the end of the quarter, and a cash runway that extends into the third quarter of 2028, past the initial Phase 3 data readouts expected in mid-2028.”

— Howard W. Robin, Q2 2026 Earnings Press Release

Back to NKTR Stock Page